PExA granted U.S. patent for sPOT technology developed to enhance analytical capabilities in exhaled breath
PExA has been granted a patent in the United States for the technology the company has developed to increase the concentration of biological material that can be analyzed using PExA’s research instrument. The sPOT technology has previously been granted patent protection in Sweden, and patent applications have been filed in additional markets.
PExA has developed a research instrument that enables unique, non-invasive sampling from the smallest airways, where many lung diseases are believed to originate. Through the use of sPOT technology, the amount of biological material in exhaled breath samples can be concentrated, thereby improving the conditions for subsequent analysis.
“The sPOT technology is an important part of the technical solutions used with our analytical instrument. Being granted additional patents for this technology in more markets strengthens our leading position in the field,” says Tomas Gustafsson, CEO of PExA.
PExA’s research instrument is used, among others, by Professor Sandra Lindstedt and her research team in Lund to develop a method for identifying lung cancer at an early stage through analysis of particles in exhaled air. In their research, Lindstedt and her team have identified a number of markers in the PEx-samples that can be linked to cancer. According to the research group, analyses of the PEx-samples also indicate that differences between various types of lung cancer can be observed, and Lindstedt and her team were recently awarded SEK 27 million from The Swedish Cancer Society to further develop the method, as previously communicated by PExA.
Traditional tests for lung cancer are associated with extensive procedures, and for tumors to be detected using conventional CT imaging, they must first grow to a sufficient size. By instead analyzing exhaled breath, there is a potential to identify lung cancer at an earlier stage, where the possibilities for effective treatment are significantly greater.
For further information, please contact:
Tomas Gustafsson, CEO, info@pexa.se
About PExA AB:
PExA AB PExA AB (556956-9246) has developed the PExA 2.1, a patented research instrument that helps researchers intelligently collect biological samples from the smallest airways through a simple exhalation maneuver. PExA’s technology is currently used by prominent research groups in several different countries and research with the instrument has resulted in approximately 50 scientific publications, which serve as reference material for PExA’s method. The company’s long-term goal is to market and sell diagnostic instruments for popular diseases (e.g. lung cancer and COPD) to be used globally for diagnosis or general screening at facilities where care is offered. The company intends at the time it is relevant to sell to clinics to have developed more patient-friendly, flexible and commercial products, which means that PExA addresses a significantly wider market, which today includes several million patients globally.
PExA’s B share is listed on the Spotlight Stock Market.